Effect of dietary fructooligosaccharide supplementation on internal organs Salmonella colonization, immune response, ileal morphology, and ileal immunohistochemistry in laying hens challenged with Salmonella enteritidis
Effect of dietary fructooligosaccharide supplementation on internal organs Salmonella colonization, immune response, ileal morphology, and ileal immunohistochemistry in laying hens challenged with Salmonella enteritidis
复制标题
DOI：
10.3382/ps/pey101
复制
发表时间：
2018-07-01
期刊：
影响因子：
4.4
通讯作者：
Kim, Woo K.
中科院分区：
文献类型：
--
作者：
Adhikari, Pratima;Cosby, Douglas E.;Kim, Woo K.
本研究旨在评价低聚果糖（FOS）对白色来航鸡肠道沙门氏菌（SE）感染的控制效果。总共30只产蛋母鸡（白色来航鸡W 36）经口和泄殖腔接受约108个菌落形成单位的耐纳啶酸SE（SENAR）攻击，并分为3个处理：1）SENAR攻击+0.0%FOS，2）SENAR攻击+0.5%FOS（Nutraflora），和3）SENAR攻击+1.0%FOS。在感染后3天和6天（dpi）通过粪便脱落测量SENAR恢复，而在盲肠和内脏中，在感染后7天测量SENAR恢复。在第一个实验中，通过补充0.5%和1.0%的FOS，盲肠SENAR分别减少了1.0 log（10）和1.3 log（10）。在第二个实验中，通过补充0.5%和1.0%的FOS，盲肠SENAR分别降低了0.6 log（10）和0.8 log（10）。与SENAR攻击0.0%FOS相比，1.0%FOS补充组的粪便脱落显著较低。3种处理对肝脏、胆囊和卵巢的SENAR恢复无显著差异。然而，在两项实验中，SENAR激发0.0% FOS中卵巢中SENAR阳性的频率（10至40%）显着低于肝脏和胆囊（60至80%）。Toll样受体-4在1.0%FOS中显著上调，干扰素γ在0.5和1.0%FOS中显著上调。所有治疗组的回肠绒毛高度和隐窝深度的组织学测量结果相似。回肠样品的免疫组织化学分析显示，免疫球蛋白A阳性细胞随着FOS浓度的增加而增加，在1.0%时达到显著性，以及回肠中细胞因子基因表达的改变。此外，FOS补充还降低了盲肠SENAR和粪便SENAR水平。总的来说，这些结果表明，膳食中补充FOS可能会损害SE的发病机制，同时调节肠道相关淋巴组织内的体液免疫。
A study was conducted to evaluate the efficacy of fructooligosaccharides (FOS) in controlling the infection of Salmonella Enteritidis (SE) in White Leghorns. A total of 30 laying hens (white leghorns W36) were challenged both orally and cloacally with approximately 108 colony-forming units of nalidxic acid resistant SE (SENAR) and divided into 3 treatments: 1) SENAR challenged + 0.0% FOS, 2) SENAR challenged + 0.5% FOS (Nutraflora), and 3) SENAR challenged + 1.0% FOS. SENAR recovery via fecal shedding was measured at 3- and 6-d post-infection (dpi), whereas in the ceca and internal organs, SENAR recovery was measured at 7-d post-infection. In the first experiment, there was a 1.0 log(10) and a 1.3 log(10) reduction in cecal SENAR by supplementation of FOS at 0.5 and 1.0%, respectively. In the second experiment, there was a 0.6 log(10) and a 0.8 log(10) reduction in cecal SENAR by supplementation of FOS at 0.5 and 1.0%, respectively. Fecal shedding was significantly lower in 1.0% FOS supplemented groups compared to SENAR challenge 0.0% FOS. There was no significant difference among the 3 treatments on SENAR recovery in liver with gall bladder and ovaries. However, the frequency of positive SENAR in the ovaries (10 to 40%) in SENAR challenge 0.0% FOS was significantly lower than liver with gall bladder (60 to 80%) in both experiments. There was a significant upregulation of toll-like receptor-4 in 1.0% FOS and interferon gamma in both 0.5 and 1.0% FOS. Histologic measurements of ileal villi height and crypt depth were similar across all treatments. Immunohistochemistry analyses of ileal samples showed that immunoglobulin A positive cells increased as FOS concentration increased reaching significance at 1.0% as well as altered cytokine gene expression in the ileum. Further, FOS supplementation also reduced cecal SENAR and feces SENAR levels. Collectively, the results suggest that dietary supplementation with FOS may impair SE pathogenesis while modulating humoral immunity within the gut-associated lymphoid tissue.